TransMedics Group Inc vs State Street Technology Select Sector SPDR ETF — how do they compare? TransMedics Group Inc trades at $85.89 (market cap $3.06B), while State Street Technology Select Sector SPDR ETF trades at $188.04. The key difference: State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| TMDX | XLK | |
|---|---|---|
Market Cap | $3.06B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $150.42 | $198.21 |
52-Week Low | $61.99 | $127.49 |
Enterprise Value | $3.46B | — |
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
XLK trades at $187.87, up 0.3% today, with a bullish technical signal from moving averages and support at $185. The ETF holds a concentrated mega-cap tech strategy with a low 0.08% expense ratio, though key financial ratios are unavailable. Recent news highlights sector inflows and AI-driven software shifts.
Outlook is supported by tech sector momentum and AI adoption, but risks include high concentration in top holdings and valuation sensitivity. Analysts favor XLK for its cost efficiency and exposure to AI growth, yet investors face volatility from economic and competitive pressures.
Trailing returns across standard periods
Latest headlines on both assets
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →